We use cookies to improve your experience on this website. Read More Allow Cookies

Teva Sponsors Vital Cancer Research

Posted on: 14 Jul 2015

Teva Sponsors Vital Cancer Research


‘Pictured at the Cork Cancer Research Centre are left to right: Dr. Pat Forde, Researcher, CCRC; Yvonne Kavanagh, TEVA; Dr Brian Bird, Consultant Oncologist, Bon Secours Hospital Cork, & CCRC collaborator; Rebecca Gardiner, Fellowship recipient and Medic at the CCRC’.



Teva Pharmaceuticals Ireland (Teva) are delighted to announce its continued support for cancer research in Ireland by contributing a research grant to the Cork Cancer Research Centre (CCRC).



The CCRC is a collaborative research centre involving interdisciplinary cancer research with the Cork University Hospital and University College Cork and has become internationally recognised for its ground-breaking cancer research. The CCRC is currently operating a joint programme of research with Copenhagen University Hospital in Denmark. This is the second year in which Teva’s contribution has enabled this research partnership to flourish: last year’s funding allowed vital research to be carried out in the area of lung cancer.



Sandra Gannon, General Manager of Teva, commenting on Teva’s sponsorship of the CCRC Fellowship noted: ‘We are delighted to once again support the CCRC in their important work.  Last year’s sponsorship supported important new research in lung cancer, a condition which is the fifth most common cancer in Ireland with over 2,000 new cases diagnosed each year.



‘As the largest supplier of medicines to the Irish State and a company with a significant medicines portfolio dedicated to cancer treatment, we hope this fellowship award will help the CCRC continue its outstanding record of research on cancer prevention, treatment and care.’



Dr Brian Bird Senior Clinical Investigator CCRC and Consultant Medical Oncologist Bon Secours Cork, commenting on the Fellowship and Teva’s sponsorship noted:

‘At CCRC our vision is for a future free of cancer, this objective is at the core of everything we do. We work to harness the patient's own immune system to defeat their cancer.’



We would particularly like to thank Teva for their continued support. It is important Ireland contributes to global efforts to develop effective treatments for cancer, not least to ensure Irish patients can benefit from new and innovative treatments. Teva’s support assists this ongoing effort’.